Stem-Cell Derived Therapies: From Source To Site

Stem cells are the backbone of many allogeneic, “off-the-shelf” cell therapies. Whether they’re collected from healthy donors, obtained from cord blood banks, or made from healthy somatic cells (iSPCs), where these stem cells come from affects product development and supply chain logistics. A critical step in this supply chain is cryopreservation, which brings its own set of challenges and questions. What temperatures are ideal to maintain product potency while avoiding degradation and damage? How do you build a reliable cold chain to bring these products to patients? And, once onsite, how do you work with existing infrastructure to truly allow for an “off-the-shelf” therapy?

To discuss these questions and considerations regarding stem-cell-derived therapies, Cell & Gene Live Editor, Tyler Menichiello, was joined by Dr. Colleen Delaney, MD, Chief Scientific and Medical Officer at both Coeptis Therapeutics and Deverra Therapeutics, Kathryn Golden, SVP, Technical Operations and Cell Manufacturing at bit.bio and Co-founder at Sunflower Therapeutics, and Michael Mehler, Commercial Operations Lead at ZS: Global Management Consulting and Technology Firm.

Available on-demand thanks to the support of Charter Medical and Bio-Techne.